Literature DB >> 15121647

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Jeffrey H Meyer1, Alan A Wilson, Sandra Sagrati, Doug Hussey, Anna Carella, William Z Potter, Nathalie Ginovart, Edgar P Spencer, Andy Cheok, Sylvain Houle.   

Abstract

OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [(11)C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic doses. The relationship between dose and occupancy was also investigated.
METHOD: Striatal 5-HTT binding potential was measured in 77 subjects before and after 4 weeks of medication administration. Binding potential is proportional to the density of receptors not blocked by medication. Subjects received citalopram, fluoxetine, sertraline, paroxetine, or extended-release venlafaxine. Healthy subjects received subtherapeutic doses; subjects with mood and anxiety disorders received therapeutic doses. Percent reduction in 5-HTT binding potential for each medication and dose was calculated. To obtain test-retest data, binding potential was measured before and after 4 weeks in six additional healthy subjects.
RESULTS: Substantial occupancy occurred at subtherapeutic doses for all SSRIs. Compared to test-retest data, each drug at the minimum therapeutic dose had a significant effect on striatal 5-HTT binding potential. Mean occupancy at this dose was 76%-85%. At higher plasma SSRI concentrations, 5-HTT occupancy tended to increase above 80%. For each drug, as the dose (or plasma level) increased, occupancy increased nonlinearly, with a plateau for higher doses.
CONCLUSIONS: At tolerable doses, SSRIs have increasing occupancy with increasing plasma concentration or dose. Occupancy of 80% across five SSRIs occurs at minimum therapeutic doses. This suggests that 80% 5-HTT blockade is important for therapeutic effect. Occupancy should be measured during development of antidepressant compounds targeting the 5-HTT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121647     DOI: 10.1176/appi.ajp.161.5.826

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  118 in total

1.  The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast.

Authors:  Meredith M Rainey; Daniel Korostyshevsky; Sean Lee; Ethan O Perlstein
Journal:  Genetics       Date:  2010-05-10       Impact factor: 4.562

Review 2.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

3.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

4.  When common clinical practice meets evidence-based medicine.

Authors:  David Feifel
Journal:  Psychiatry (Edgmont)       Date:  2006-12

5.  The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.

Authors:  Brandon Mansoor; Manivel Rengasamy; Robert Hilton; Giovanna Porta; Jiayan He; Anthony Spirito; Graham J Emslie; Taryn L Mayes; Gregory Clarke; Karen Dineen Wagner; Wael Shamseddeen; Boris Birmaher; Neal Ryan; David Brent
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-11       Impact factor: 2.576

6.  A dose-finding study of duloxetine based on serotonin transporter occupancy.

Authors:  Akihiro Takano; Kazutoshi Suzuki; Jun Kosaka; Miho Ota; Shoko Nozaki; Yoko Ikoma; Shuji Tanada; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2006-02-28       Impact factor: 4.530

7.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

8.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

9.  Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Authors:  Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2013-03-01       Impact factor: 13.382

10.  Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.

Authors:  Aaron S Heller; Tom Johnstone; Sharee N Light; Michael J Peterson; Gregory G Kolden; Ned H Kalin; Richard J Davidson
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.